A Randomised Double-blind Cross-over Patient Preference Study of Pazopanib Versus Sunitinib in Treatment naive Locally Advanced or Metastatic Renal Cell Carcinoma
Phase of Trial: Phase III
Latest Information Update: 22 Jul 2017
At a glance
- Drugs Pazopanib (Primary) ; Sunitinib
- Indications Renal cell carcinoma
- Focus Adverse reactions; Therapeutic Use
- Acronyms PISCES
- Sponsors GlaxoSmithKline; Novartis
- 28 Apr 2016 The study is "Completed" in Finland, Germany, and Italy.
- 03 Apr 2016 Status changed from active, no longer recruiting to completed.
- 02 Dec 2015 Planned End Date changed from 1 Sep 2014 to 1 Jun 2016 as per ClinicalTrials.gov record.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History